Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Sibutramine AI simulator
(@Sibutramine_simulator)
Hub AI
Sibutramine AI simulator
(@Sibutramine_simulator)
Sibutramine
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise. It has been associated with an increased risk of myocardial infarction and ischaemic stroke and has been withdrawn from the market in 2010 in several countries and regions including Australia, Canada, China, the European Union, Hong Kong, India, Mexico, New Zealand, the Philippines, Thailand, the United Kingdom, and the United States. It was never approved in Japan. However, the drug remains available in some countries.[which?]
Sibutramine was originally developed in 1988 by Boots in Nottingham, UK, and manufactured and marketed by Abbott Laboratories and sold under a variety of brand names including Reductil, Meridia, Siredia, and Sibutrex before its withdrawal 2010 from most markets. It was classified as a Schedule IV controlled substance in the United States.
As of 2018, the US Food and Drug Administration (FDA) still found sibutramine in over 700 diet supplements marketed as "natural", "traditional", or "herbal remedies".
Sibutramine has been used to produce appetite suppression for the purpose of attaining weight loss in the treatment of patients with obesity.[citation needed]
Sibutramine is contraindicated in patients with:
A higher number of cardiovascular events has been observed in people taking sibutramine versus control (11.4% vs. 10.0%). In 2010, the FDA noted the concerns that sibutramine increases the risk of heart attacks and strokes in patients with a history of cardiovascular disease.
Frequently encountered side effects include dry mouth, paradoxically increased appetite, nausea, strange taste in the mouth, abdominal pain, constipation, insomnia, dizziness, drowsiness, menstrual cramps, headache, flushing, or joint/muscle pain.[citation needed]
In a 2016 Cochrane review, sibutramine was found to substantially increase blood pressure and heart rate in some patients, in the updated review in 2021 sibutramine was not included since the drug had been withdrawn from the market. When used, regular blood pressure monitoring needed to be performed.[citation needed]
Sibutramine
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants. Until 2010, it was widely marketed and prescribed as an adjunct in the treatment of obesity along with diet and exercise. It has been associated with an increased risk of myocardial infarction and ischaemic stroke and has been withdrawn from the market in 2010 in several countries and regions including Australia, Canada, China, the European Union, Hong Kong, India, Mexico, New Zealand, the Philippines, Thailand, the United Kingdom, and the United States. It was never approved in Japan. However, the drug remains available in some countries.[which?]
Sibutramine was originally developed in 1988 by Boots in Nottingham, UK, and manufactured and marketed by Abbott Laboratories and sold under a variety of brand names including Reductil, Meridia, Siredia, and Sibutrex before its withdrawal 2010 from most markets. It was classified as a Schedule IV controlled substance in the United States.
As of 2018, the US Food and Drug Administration (FDA) still found sibutramine in over 700 diet supplements marketed as "natural", "traditional", or "herbal remedies".
Sibutramine has been used to produce appetite suppression for the purpose of attaining weight loss in the treatment of patients with obesity.[citation needed]
Sibutramine is contraindicated in patients with:
A higher number of cardiovascular events has been observed in people taking sibutramine versus control (11.4% vs. 10.0%). In 2010, the FDA noted the concerns that sibutramine increases the risk of heart attacks and strokes in patients with a history of cardiovascular disease.
Frequently encountered side effects include dry mouth, paradoxically increased appetite, nausea, strange taste in the mouth, abdominal pain, constipation, insomnia, dizziness, drowsiness, menstrual cramps, headache, flushing, or joint/muscle pain.[citation needed]
In a 2016 Cochrane review, sibutramine was found to substantially increase blood pressure and heart rate in some patients, in the updated review in 2021 sibutramine was not included since the drug had been withdrawn from the market. When used, regular blood pressure monitoring needed to be performed.[citation needed]
Recent media
Recent media